Results 81 to 90 of about 16,645 (269)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease

Research and Practice in Thrombosis and Haemostasis, 2020
Background Little evidence is available for treatment of pediatric venous thromboembolism (VTE). Large randomized controlled trials are challenging in children.
Cornelia Heleen vanOmmen, Manuela Albisetti, Anthony K. Chan, Jeremie Estepp, Julie Jaffray, Gili Kenet, Guy Young, Jay Dave, Michael A. Grosso, Anil Duggal   +9 more
doaj   +1 more source

Clinical considerations on the posology of direct oral anticoagulants [PDF]

, 2016
Los anticoagulantes dicumarínicos han demostrado su eficacia en pacientes con fibrilación auricular no valvular. Sin embargo, presentan desventajas como la necesidad de ajustar la dosis y la interacción con fármacos y alimentos.
Avendaño Solá, C., González Juanatey, J.R., Peñataro Sáez, J.   +2 more
core   +2 more sources

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. [PDF]

, 2018
© 2018 Vimalesvaran et al. This work is published and licensed by Dove Medical Press Limited.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.
Dockrill, Seth J, Gorog, Diana, Vimalesvaran, Kavitha   +2 more
core   +3 more sources

Endoscopic Hemostasis for Gastrointestinal Stromal Tumor Hemorrhage: A Case Series and Retrospective Analysis of Risk Factors

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives Gastrointestinal stromal tumors (GISTs) are vascular tumors that can cause significant gastrointestinal hemorrhage. While endoscopic treatment is common for other hemorrhagic disorders, its role in GIST‐related hemorrhage remains unclear.
Karen Kimura, Chikamasa Ichita, Chihiro Sumida, Takashi Nishino, Miki Nagayama, Akiko Sasaki   +5 more
wiley   +1 more source

Distribution of anti‐factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban

Journal of Arrhythmia
Background The distribution of anti‐factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated. Methods and Results The trough and peak AXA were measured in 19 NVAF patients taking
Shotaro Hiramatsu, Hiroyuki Osanai, Yuichiro Sakai, Yoshiki Sogo, Yuki Tanaka, Hikari Matsumoto, Shun Miyamoto, Kensuke Tagahara, Kenji Arai, Takashi Watanabe, Yusuke Sakamoto, Teruhiro Sakaguchi, Shioh Oguchi, Takahiro Kanbara, Yoshihito Nakashima, Hiroshi Asano, Masayoshi Ajioka   +16 more
doaj   +1 more source

Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. [PDF]

PLoS ONE, 2014
Edoxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unexplored.Medline, Embase and Web of Science were searched to March 8, 2014 for prospective ...
Shuang Li, Baoxin Liu, Dachun Xu, Yawei Xu   +3 more
doaj   +1 more source

Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis

Heliyon, 2023
Background and aim: Current observational studies have compared the effectiveness and safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still disputed.
Bailin Zhang, Winglam Cheng, Wulamiding Kaisaier, Zhenbang Gu, Wengen Zhu, Qiuhua Jiang   +5 more
doaj   +1 more source

The Risk of Colonoscopy‐related Bleeding in Patients With or Without Continued Treatment With an Antithrombotic Agent

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives We prospectively investigated the risk of colonoscopy‐related bleeding in relation to antithrombotic treatment. Methods This prospective, observational, single‐center cohort study (NCT02594813) enrolled consecutive patients who underwent colonoscopy, including the removal of colorectal polyps, regardless of the continuation of ...
Emi Nonaka, Ichitaro Horiuchi, Akira Horiuchi, Satoshi Ukai, Noriko Takahata, Kimihiko Oishi   +5 more
wiley   +1 more source

Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation

Journal of Pharmaceutical Health Care and Sciences
Background Edoxaban is used as an anti-coagulant to prevent cardioembolic infarction, deep vein thrombosis, and pulmonary embolism. Edoxaban pharmacokinetics have been reported to be affected by several factors such as renal function, age, body weight ...
Satoshi Ueshima, Daiki Hira, Sayana Matsuda, Rio Michihata, Yohei Tabuchi, Tomoya Ozawa, Hideki Itoh, Moritake Iguchi, Masaharu Akao, Takanori Aizawa, Asami Kashiwa, Satoshi Shizuta, Takeru Makiyama, Yoshihisa Nakagawa, Minoru Horie, Tomohiro Terada, Toshiya Katsura   +16 more
doaj   +1 more source

Direct oral anticoagulants versus warfarin: is new always better than the old? [PDF]

, 2018
About 1.4 British million people are at risk of strokes due to non-valvular atrial fibrillation (AF) necessitating long-term anticoagulation. The vitamin K antagonist, warfarin, has a long half-life and narrow therapeutic range necessitating regular ...
Burn, John, Pirmohamed, Munir
core   +1 more source